Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 12, 2013, Pages

  Ramachandran, G ^a   Bhavani, P K ^a   Hemanth Kumar, A K ^a   Srinivasan, R ^a   Raja, K ^b   Sudha, V ^a   Venkatesh, S ^a   Chandrasekaran, C ^b   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b Government Hospital of Thoracic Medicine   (India)

Author keywords

HIV; Pharmacokinetics; Rifabutin; Ritonavir; TB

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; STREPTOMYCIN; TENOFOVIR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REFERENCE VALUE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; POLYPHARMACY; PYRIDINES; RIFABUTIN; RITONAVIR; TUBERCULOSIS;

EID: 84888093370     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0390     Document Type: Article

References (26)

1. Brinkhof M W, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521. (Pubitemid 351411886)
2. Lawn S D, Myer L, Bekker L G, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and challenges for tuberculosis control. AIDS 2006; 20: 1605-1612. (Pubitemid 44162402)
3. Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45: 921-925.
4. Vanhove G F, Schapiro J M, Winters M A, et al. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA 1996; 276: 1955-1956. (Pubitemid 26427720)
5. Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of anti-tuberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
6. Gonzalez-Montaner L J, Natal S, Yonchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis 1994; 75: 341-347. (Pubitemid 24336530)
7. Burman W J, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis 1999; 28: 419-430. (Pubitemid 29242513)
8. Narita M, Stambaugh J J, Hollender E S, Jones D, Pitchenik A E, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
9. Perucca E, Grimaldi R, Frigo G M, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988; 34: 595-599.
10. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356. (Pubitemid 43209091)
11. Cato A III, Cavanaugh J, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414-421. (Pubitemid 28214964)
12. Gallicano K, Khaliq Y, Carignan G, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001; 70: 149-158. (Pubitemid 32777767)
13. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-1311.
14. Khachi H, O'Connell R, Ladenheim D, et al. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009; 64: 871-873.
15. Suhashni N, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. 18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011. Boston, MA, USA: CROI, 2011: Paper no. 650. http://www.retroconference.org /2011/Abstracts Accessed November 2012.
16. Sekar V, Lavreys L, van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54: 4440-4444.
17. Ford S L, Chen Y, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 2008; 52: 534-538. (Pubitemid 351170825)
18. Zhang X, Fettner S, Zwanziger E, et al. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother 2011; 55: 680-687.
19. Zhang J, Zhu L, Stonier M, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother 2011; 66: 2075-2082.
20. Hemanth Kumar A K, Sudha V, Ramachandran G. Simple and rapid liquid chromatography method for determination of rifabutin in human plasma. SAARC J Tuberc Lung Dis HIV/AIDS 2013; 9: 26-29.
21. Turner M L, Reed-Walker K, King J R, et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 331-341. (Pubitemid 36044016)
22. Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis 2002; 35: 1106-1112. (Pubitemid 35239471)
23. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491. (Pubitemid 40628637)
24. Gurumurthy P, Ramachandran G, Hemanth Kumar A K, et al. Decreased bioavailability of rifampin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother 2004; 48: 4473-4475. (Pubitemid 39434921)
25. Jenny-Avital E R, Josepk K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48: 1471-1474.
26. Moultrie H, McIlleron H, Sawry S, et al. High rate of neutropenia in young children receiving concomitant rifabutin and lopinavir/ritonavir. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012. Seattle, WA, USA: CROI, 2012: Abstract S-177. http://www.retroconference.org/ 2012/Abstracts Accessed November 2012.